gemcitabine + FOLFIRINOX

This refers to a treatment strategy or combination of chemotherapy regimens evaluated in the CONKO-007 clinical trial for locally advanced, unresectable pancreatic cancer. The trial, sponsored by the University of Erlangen-Nürnberg Medical School, compares the efficacy of chemoradiotherapy (using gemcitabine) against chemotherapy alone (either gemcitabine or FOLFIRINOX) following an induction phase of chemotherapy. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while FOLFIRINOX is a multi-drug regimen consisting of oxaliplatin (DNA cross-linker), irinotecan (topoisomerase I inhibitor), leucovorin (folinic acid), and 5-fluorouracil (thymidylate synthase inhibitor). The study aims to determine if adding radiotherapy to these systemic treatments improves overall survival in patients with non-metastatic, non-resectable pancreatic ductal adenocarcinoma.

Other names

gemcitabine plus FOLFIRINOXCONKO-007 regimenCONKO007 regimenCONKO 007 regimen